KRAS and lung carcinoma: In the first set (Figure 1A), we performed three genome scale screens with the MEK inhibitor trametinib, in the NRAS-mutant lung cancer cell line H1299 (NRASQ61K), the BRAF-mutant lung cancer cell line HCC364 (BRAFV600E), and the KRAS-mutant lung cancer cell line CALU1 (KRASG12C).